Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment
Open accessThe DOI matches its Crossref record; 264 of the 264 references it cites were found in a registry or an index.
Abstract
Cancer cells have adapted to rapid tumor growth and evade immune attack by reprogramming their metabolic pathways. Glutamine is an important nitrogen resource for synthesizing amino acids and nucleotides and an important carbon source in the tricarboxylic acid (TCA) cycle and lipid biosynthesis pathway. In this review, we summarize the significant role of glutamine metabolism in tumor development and highlight the vulnerabilities of targeting glutamine metabolism for effective therapy. In particular, we review the reported drugs targeting glutaminase and glutamine uptake for efficient cancer treatment. Moreover, we discuss the current clinical test about targeting glutamine metabolism and the prospective direction of drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, despite promising results in preclinical and early clinical trials, their clinical effectiveness is often compromised by resistance mechanisms due to tumor heterogeneity and metabolic plasticity, as well as toxicity to normal tissue [63].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [63]
The cited source says what the claim attributes to it.
In the citing paper
“Targeting the glutamine dependency of cancer cells is a promising therapeutic strategy for cancer and many agents targeting various steps of glutamine metabolism are currently in development [63].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 1×
“For example, cancer cells produce lactate through glycolysis to satisfy their energy needs even in the presence of oxygen, known as the Warburg effect (Ward and Thompson, 2012).”
BackgroundMetabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990 · cited 3×
“In addition, the intracellular glutamine can maintain redox homeostasis through many sophisticated mechanisms (Son et al., 2013; Koppula et al., 2018; Jaganjac et al., 2020; Ying et al., 2021).”
BackgroundCancer metabolism: looking forward
Martínez-Reyes, I., & Chandel, N. S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,824
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation
Jain, M., Nilsson, R., Sharma, S., Madhusudhan, N., Kitami, T., Souza, A. L., Kafri, R., Kirschner, M. W., Clish, C. B., & Mootha, V. K. (2012) · Science · doi:10.1126/science.1218595 · Cited by 1,403
Glutathione Homeostasis and Functions: Potential Targets for Medical Interventions
Lushchak, V. I. (2012) · Journal of Amino Acids · doi:10.1155/2012/736837 · Cited by 1,266 · cited 12×
“The reported drugs mainly aim at glutamine transporters, glutaminase, aminotransferases, GSH, and NADPH synthesis (Table 1) (Choi and Park, 2018; Li L. et al., 2019).”
BackgroundInfluentialα-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming
Liu, P.-S., Wang, H., Li, X., Chao, T., Teav, T., Christen, S., Di Conza, G., Cheng, W.-C., Chou, C.-H., Vavakova, M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3796 · Cited by 1,264
Glutamine and cancer: cell biology, physiology, and clinical opportunities
Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69600 · Cited by 1,262
Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation
Cruzat, V., Macedo Rogero, M., Noel Keane, K., Curi, R., & Newsholme, P. (2018) · Nutrients · doi:10.3390/nu10111564 · Cited by 1,261 · cited 3×
“Besides cancer cells, glutamine also participates in the immune cells ’ proliferation, promoting the secretion of pro-in fl ammatory cytokines (Vergadi et al., 2017; Cruzat et al., 2018).”
BackgroundInfluentialGlutamine: Metabolism and Immune Function, Supplementation and Clinical Translation
Cruzat, V., Macedo Rogero, M., Noel Keane, K., Curi, R., & Newsholme, P. (2018) · doi:10.20944/preprints201809.0459.v1 · Cited by 1,261
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169
Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization
Vergadi, E., Ieronymaki, E., Lyroni, K., Vaporidi, K., & Tsatsanis, C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601515 · Cited by 1,148
Metabolic heterogeneity in human lung tumors
Hensley, C. T., Faubert, B., Yuan, Q., Lev-Cohain, N., Jin, E., Kim, J., Jiang, L., Ko, B., Skelton, R., Loudat, L., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.034 · Cited by 1,138 · cited 1×
“Firstly, considering the high tumor heterogeneity, various tumors or different regions within the same tumor can exhibit distinct metabolic pro fi les (Hensley et al., 2016).”
BackgroundAntitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer
Gross, M. I., Demo, S. D., Dennison, J. B., Chen, L., Chernov-Rogan, T., Goyal, B., Janes, J. R., Laidig, G. J., Lewis, E. R., Li, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0870 · Cited by 1,068
Glutamine reliance in cell metabolism
Yoo, H. C., Yu, Y. C., Sung, Y., & Han, J. M. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00504-8 · Cited by 1,021
BAP1 links metabolic regulation of ferroptosis to tumour suppression
Zhang, Y., Shi, J., Liu, X., Feng, L., Gong, Z., Koppula, P., Sirohi, K., Li, X., Wei, Y., Lee, H., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0178-0 · Cited by 1,013
Koppula, P., Zhang, Y., Zhuang, L., & Gan, B. (2018) · Cancer Communications · doi:10.1186/s40880-018-0288-x · Cited by 915
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
Wang, J.-B., Erickson, J. W., Fuji, R., Ramachandran, S., Gao, P., Dinavahi, R., Wilson, K. F., Ambrosio, A. L. B., Dias, S. M. G., Dang, C. V., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.009 · Cited by 821
Nazio, F., Strappazzon, F., Antonioli, M., Bielli, P., Cianfanelli, V., Bordi, M., Gretzmeier, C., Dengjel, J., Piacentini, M., Fimia, G. M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2708 · Cited by 780
Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism
Johnson, M. O., Wolf, M. M., Madden, M. Z., Andrejeva, G., Sugiura, A., Contreras, D. C., Maseda, D., Liberti, M. V., Paz, K., Kishton, R. J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.001 · Cited by 715
Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine
Zhang, J., Pavlova, N. N., & Thompson, C. B. (2017) · The EMBO Journal · doi:10.15252/embj.201696151 · Cited by 651
ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer
van Geldermalsen, M., Wang, Q., Nagarajah, R., Marshall, A. D., Thoeng, A., Gao, D., Ritchie, W., Feng, Y., Bailey, C. G., Deng, N., et al. (2016) · Oncogene · doi:10.1038/onc.2015.381 · Cited by 580
Timmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573
Targeting glutamine metabolism as a therapeutic strategy for cancer
Jin, J., Byun, J.-K., Choi, Y.-K., & Park, K.-G. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00971-9 · Cited by 550
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1666 · Cited by 513
Schulte, M. L., Fu, A., Zhao, P., Li, J., Geng, L., Smith, S. T., Kondo, J., Coffey, R. J., Johnson, M. O., Rathmell, J. C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4464 · Cited by 494
Bhutia, Y. D., Babu, E., Ramachandran, S., & Ganapathy, V. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3745 · Cited by 481
Pyruvate carboxylase is required for glutamine-independent growth of tumor cells
Cheng, T., Sudderth, J., Yang, C., Mullen, A. R., Jin, E. S., Matés, J. M., & DeBerardinis, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016627108 · Cited by 475
Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131859 · Cited by 456
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis
Xiang, Y., Stine, Z. E., Xia, J., Lu, Y., O’Connor, R. S., Altman, B. J., Hsieh, A. L., Gouw, A. M., Thomas, A. G., Gao, P., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75836 · Cited by 409
Jacque, N., Ronchetti, A. M., Larrue, C., Meunier, G., Birsen, R., Willems, L., Saland, E., Decroocq, J., Maciel, T. T., Lambert, M., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621870 · Cited by 387
Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer
Yang, J., Zhou, Y., Xie, S., Wang, J., Li, Z., Chen, L., Mao, M., Chen, C., Huang, A., Chen, Y., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02012-7 · Cited by 379
Self-citationEdwards, D. N., Ngwa, V. M., Raybuck, A. L., Wang, S., Hwang, Y., Kim, L. C., Cho, S. H., Paik, Y., Wang, Q., Zhang, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140100 · Cited by 377
Jin, L., Li, D., Alesi, G. N., Fan, J., Kang, H.-B., Lu, Z., Boggon, T. J., Jin, P., Yi, H., Wright, E. R., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.006 · Cited by 370
The molecular determinants of de novo nucleotide biosynthesis in cancer cells
Tong, X., Zhao, F., & Thompson, C. B. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.01.002 · Cited by 351 · cited 1×
“As the most abundant non-essential amino acid in the blood and muscle, glutamine can provide energy and a precursor for the biosynthesis of nucleotides, amino acids, and lipids (Tong et al., 2009; Altman et al., 2016; Choi and Coloff, 2019; Cooper et al., 2023; Jin et al., 2023).”
BackgroundZhang, G., He, P., Tan, H., Budhu, A., Gaedcke, J., Ghadimi, B. M., Ried, T., Yfantis, H. G., Lee, D. H., Maitra, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0209 · Cited by 350
Sloan, J. L., & Mager, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23740 · Cited by 342
SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells
Yan, Y., Teng, H., Hang, Q., Kondiparthi, L., Lei, G., Horbath, A., Liu, X., Mao, C., Wu, S., Zhuang, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39401-9 · Cited by 341
Cystine-Glutamate Transporter SLC7A11 in Cancer Chemosensitivity and Chemoresistance
Huang, Y., Dai, Z., Barbacioru, C., & Sadée, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4267 · Cited by 340
Erratum: From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.114 · Cited by 339
Targeting ASCT2‐mediated glutamine uptake blocks prostate cancer growth and tumour development
Wang, Q., Hardie, R., Hoy, A. J., van Geldermalsen, M., Gao, D., Fazli, L., Sadowski, M. C., Balaban, S., Schreuder, M., Nagarajah, R., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4518 · Cited by 338
Mullen, A. R., Hu, Z., Shi, X., Jiang, L., Boroughs, L. K., Kovacs, Z., Boriack, R., Rakheja, D., Sullivan, L. B., Linehan, W. M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.037 · Cited by 337
Ammonia Derived from Glutaminolysis Is a Diffusible Regulator of Autophagy
Eng, C. H., Yu, K., Lucas, J., White, E., & Abraham, R. T. (2010) · Science Signaling · doi:10.1126/scisignal.2000911 · Cited by 334
Jin, L., Chun, J., Pan, C., Kumar, A., Zhang, G., Ha, Y., Li, D., Alesi, G. N., Kang, Y., Zhou, L., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2017.11.025 · Cited by 327
Glutamine transporters in mammalian cells and their functions in physiology and cancer
Bhutia, Y. D., & Ganapathy, V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.12.017 · Cited by 325
Targeting Glutamine Metabolism for Cancer Treatment
Choi, Y.-K., & Park, K.-G. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.178 · Cited by 317
Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism
Biancur, D. E., Paulo, J. A., Małachowska, B., Quiles Del Rey, M., Sousa, C. M., Wang, X., Sohn, A. S. W., Chu, G. C., Gygi, S. P., Harper, J. W., et al. (2017) · Nature Communications · doi:10.1038/ncomms15965 · Cited by 315
ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy
Dewaele, M., Maes, H., & Agostinis, P. (2010) · Autophagy · doi:10.4161/auto.6.7.12113 · Cited by 306
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B.-J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11971 · Cited by 290 · cited 1×
“Inhibiting GPT2 with AOA can signi fi cantly delay the xenograft growth of PIK3CA-mutated colon cancer cells (Hao et al., 2016).”
BackgroundEnhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy
Yang, W.-H., Qiu, Y., Stamatatos, O., Janowitz, T., & Lukey, M. J. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.04.003 · Cited by 287
Cassago, A., Ferreira, A. P. S., Ferreira, I. M., Fornezari, C., Gomes, E. R. M., Greene, K. S., Pereira, H. M., Garratt, R. C., Dias, S. M. G., & Ambrosio, A. L. B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112495109 · Cited by 285
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics
Kanai, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107964 · Cited by 283
Kodama, M. (2020) · Institutional Repositories DataBase (IRDB) · Cited by 277
Xu, X., Peng, Q., Jiang, X., Tan, S., Yang, Y., Yang, W., Han, Y., Chen, Y., Oyang, L., Lin, J., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01020-1 · Cited by 276
Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases
Eng, Q. Y., Thanikachalam, P. V., & Ramamurthy, S. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.08.035 · Cited by 274
EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer
Shankar, S. (2008) · Frontiers in Bioscience · doi:10.2741/2691 · Cited by 273
The Human SLC1A5 (ASCT2) Amino Acid Transporter: From Function to Structure and Role in Cell Biology
Scalise, M., Pochini, L., Console, L., Losso, M. A., & Indiveri, C. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00096 · Cited by 265
Bröer, A., Rahimi, F., & Bröer, S. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.700534 · Cited by 251
Pochini, L., Scalise, M., Galluccio, M., & Indiveri, C. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00061 · Cited by 249
Metabolism and action of amino acid analog anti-cancer agents
Ahluwalia, G. S., Grem, J. L., Hao, Z., & Cooney, D. A. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90094-i · Cited by 240
We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine
Lemberg, K. M., Vornov, J. J., Rais, R., & Slusher, B. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1148 · Cited by 237
Elgogary, A., Xu, Q., Poore, B., Alt, J., Zimmermann, S. C., Zhao, L., Fu, J., Chen, B., Xia, S., Liu, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611406113 · Cited by 234
Jeon, Y. J., Khelifa, S., Ratnikov, B., Scott, D. A., Feng, Y., Parisi, F., Ruller, C., Lau, E., Kim, H., Brill, L. M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.006 · Cited by 230
A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3
Tajan, M., Hock, A. K., Blagih, J., Robertson, N. A., Labuschagne, C. F., Kruiswijk, F., Humpton, T. J., Adams, P. D., & Vousden, K. H. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.005 · Cited by 230 · cited 1×
“The arginine accumulation within tumor cells can activate mTORC1 signal transduction and aid in tumor growth and metabolic adaptation, while aspartic acid can participate in tumor cell nucleotide synthesis and TCA cycle (Tajan et al., 2018; Lowman et al., 2019).”
BackgroundTargeting glutamine transport to suppress melanoma cell growth
Wang, Q., Beaumont, K. A., Otte, N. J., Font, J., Bailey, C. G., van Geldermalsen, M., Sharp, D. M., Tiffen, J. C., Ryan, R. M., Jormakka, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28749 · Cited by 224
Xiang, L., Mou, J., Shao, B., Wei, Y., Liang, H., Takano, N., Semenza, G. L., & Xie, G. (2019) · Cell Death & Disease · doi:10.1038/s41419-018-1291-5 · Cited by 223
Yang, H., Zhou, L., Shi, Q., Zhao, Y., Lin, H., Zhang, M., Zhao, S., Yang, Y., Ling, Z., Guan, K., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201591041 · Cited by 222
The Diverse Functions of Non-Essential Amino Acids in Cancer
Choi, B.-H., & Coloff, J. L. (2019) · Cancers · doi:10.3390/cancers11050675 · Cited by 213 · cited 2×
“As the most abundant non-essential amino acid in the blood and muscle, glutamine can provide energy and a precursor for the biosynthesis of nucleotides, amino acids, and lipids (Tong et al., 2009; Altman et al., 2016; Choi and Coloff, 2019; Cooper et al., 2023; Jin et al., 2023).”
Backgroundvan den Heuvel, A. P. J., Jing, J., Wooster, R. F., & Bachman, K. E. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21348 · Cited by 209
Byun, J.-K., Park, M., Lee, S., Yun, J. W., Lee, J., Kim, J. S., Cho, S. J., Jeon, H.-J., Lee, I.-K., Choi, Y.-K., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.015 · Cited by 208
Thangavelu, K., Pan, C. Q., Karlberg, T., Balaji, G., Uttamchandani, M., Suresh, V., Schüler, H., Low, B. C., & Sivaraman, J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116573109 · Cited by 206
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy
Sharma, N. S., Gupta, V. K., Garrido, V. T., Hadad, R., Durden, B. C., Kesh, K., Giri, B., Ferrantella, A., Dudeja, V., Saluja, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127515 · Cited by 203 · cited 3×
“…in cancer cell proliferation and immune cell phenotypes, developing novel antitumor drugs targeting glutamine metabolism has shown promising therapeutic effects in various mouse cancer models and preclinical tests (Oh et al., 2020; Sharma et al., 2020; Edwards et al., 2021; Lee et al., 2022).”
BackgroundInfluentialKarunakaran, S., Ramachandran, S., Coothankandaswamy, V., Elangovan, S., Babu, E., Periyasamy-Thandavan, S., Gurav, A., Gnanaprakasam, J. P., Singh, N., Schoenlein, P. V., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229518 · Cited by 202
Shukla, K., Ferraris, D. V., Thomas, A. G., Stathis, M., Duvall, B., Delahanty, G., Alt, J., Rais, R., Rojas, C., Gao, P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301191p · Cited by 199
Lukey, M. J., Greene, K. S., Erickson, J. W., Wilson, K. F., & Cerione, R. A. (2016) · Nature Communications · doi:10.1038/ncomms11321 · Cited by 189
Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach
Chen, L., & Cui, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922830 · Cited by 184
Glutamine Transport and Mitochondrial Metabolism in Cancer Cell Growth
Scalise, M., Pochini, L., Galluccio, M., Console, L., & Indiveri, C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00306 · Cited by 183
Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate
Korangath, P., Teo, W. W., Sadik, H., Han, L., Mori, N., Huijts, C. M., Wildes, F., Bharti, S., Zhang, Z., Santa-Maria, C. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1200 · Cited by 182
Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2
Redis, R. S., Vela, L. E., Lu, W., Ferreira de Oliveira, J., Ivan, C., Rodriguez-Aguayo, C., Adamoski, D., Pasculli, B., Taguchi, A., Chen, Y., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.01.015 · Cited by 181
A Tale of Two Glutaminases: Homologous Enzymes with Distinct Roles in Tumorigenesis
Katt, W. P., Lukey, M. J., & Cerione, R. A. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0190 · Cited by 181
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma
Momcilovic, M., Bailey, S. T., Lee, J. T., Fishbein, M. C., Braas, D., Go, J., Graeber, T. G., Parlati, F., Demo, S., Li, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.002 · Cited by 181
Lactate and glutamine support NADPH generation in cancer cells under glucose deprived conditions
Ying, M., You, D., Zhu, X., Cai, L., Zeng, S., & Hu, X. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102065 · Cited by 180
Jin, H., Wang, S., Zaal, E. A., Wang, C., Wu, H., Bosma, A., Jochems, F., Isima, N., Jin, G., Lieftink, C., et al. (2020) · eLife · doi:10.7554/elife.56749 · Cited by 178
Emadi, A., Jun, S. A., Tsukamoto, T., Fathi, A. T., Minden, M. D., & Dang, C. V. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.12.001 · Cited by 175
Reinforce the antitumor activity of CD 8+ T cells via glutamine restriction
Nabe, S., Yamada, T., Suzuki, J., Toriyama, K., Yasuoka, T., Kuwahara, M., Shiraishi, A., Takenaka, K., Yasukawa, M., & Yamashita, M. (2018) · Cancer Science · doi:10.1111/cas.13827 · Cited by 175
Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer
Parker, S. J., Amendola, C. R., Hollinshead, K. E. R., Yu, Q., Yamamoto, K., Encarnación-Rosado, J., Rose, R. E., LaRue, M. M., Sohn, A. S. W., Biancur, D. E., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0959 · Cited by 175
Targeting Glutamine Metabolism and Redox State for Leukemia Therapy
Gregory, M. A., Nemkov, T., Park, H. J., Zaberezhnyy, V., Gehrke, S., Adane, B., Jordan, C. T., Hansen, K. C., D’Alessandro, A., & DeGregori, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3223 · Cited by 171
Varghese, S., Pramanik, S., Williams, L. J., Hodges, H. R., Hudgens, C. W., Fischer, G. M., Luo, C. K., Knighton, B., Tan, L., Lorenzi, P. L., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0430 · Cited by 171
Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer
Stuart, E. C., Scandlyn, M. J., & Rosengren, R. J. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.07.036 · Cited by 170
Targeting SLC1a5‐mediated glutamine dependence in non‐small cell lung cancer
Hassanein, M., Qian, J., Hoeksema, M. D., Wang, J., Jacobovitz, M., Ji, X., Harris, F. T., Harris, B. K., Boyd, K. L., Chen, H., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29535 · Cited by 166
The role of ASCT2 in cancer: A review
Liu, Y., Zhao, T., Li, Z., Wang, L., Yuan, S., & Sun, L. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.007 · Cited by 162
Self-citationThe NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies
Jaganjac, M., Milkovic, L., Sunjic, S. B., & Zarkovic, N. (2020) · Antioxidants · doi:10.3390/antiox9111151 · Cited by 162
Nγ-Aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site
Esslinger, C. S., Cybulski, K. A., & Rhoderick, J. F. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.11.028 · Cited by 158
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism
Encarnación-Rosado, J., Sohn, A. S. W., Biancur, D. E., Lin, E. Y., Osorio-Vasquez, V., Rodrick, T. C., González-Baerga, D., Zhao, E., Yokoyama, Y., Simeone, D. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00647-3 · Cited by 154
The Multifaceted Roles of Proline in Cell Behavior
Patriarca, E. J., Cermola, F., D’Aniello, C., Fico, A., Guardiola, O., Cesare, D. D., & Minchiotti, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.728576 · Cited by 153
Therapeutic Strategies Impacting Cancer Cell Glutamine Metabolism
Lukey, M. J., Wilson, K. F., & Cerione, R. A. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.130 · Cited by 152
Park, Y., Sohn, B. H., Johnson, R. L., Kang, M., Kim, S. B., Shim, J., Mangala, L. S., Kim, J. H., Yoo, J. E., Rodriguez‐Aguayo, C., et al. (2016) · Hepatology · doi:10.1002/hep.28223 · Cited by 152
Morotti, M., Zois, C. E., Ansari, R. E., Craze, M. L., Rakha, E. A., Fan, S., Valli, A., Haider, S., Goberdhan, D. C. I., Green, A. R., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01113-y · Cited by 152
Glutamine Addiction and Therapeutic Strategies in Lung Cancer
Vanhove, K., Derveaux, E., Graulus, G., Mesotten, L., Thomeer, M., Noben, J., Guedens, W., & Adriaensens, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020252 · Cited by 143
Zhang, Z., Liu, R., Shuai, Y., Huang, Y., Jin, R., Wang, X., & Luo, J. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0637-9 · Cited by 142
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug
Rais, R., Lemberg, K. M., Tenora, L., Arwood, M. L., Pal, A., Alt, J., Wu, Y., Lam, J., Aguilar, J. M. H., Zhao, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq5925 · Cited by 142
SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis
Greene, K. S., Lukey, M. J., Wang, X., Blank, B. S., Druso, J. E., Lin, M.-C. J., Stalnecker, C. A., Zhang, C., Abril, Y. L. N., Erickson, J. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911954116 · Cited by 140
Hopefully devoted to Q: targeting glutamine addiction in cancer
Still, E. R., & Yuneva, M. O. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.113 · Cited by 133
Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer
Coothankandaswamy, V, Cao, S., Xu, Y., Prasad, P. D., Singh, P. K., Reynolds, C. P., Yang, S., Ogura, J., Ganapathy, V, & Bhutia, Y. D. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13616 · Cited by 132
Glutaminase regulation in cancer cells: a druggable chain of events
Katt, W. P., & Cerione, R. A. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.008 · Cited by 129
The NF-κB member p65 controls glutamine metabolism through miR-23a
Rathore, M. G., Saumet, A., Rossi, J.-F., de Bettignies, C., Tempé, D., Lecellier, C.-H., & Villalba, M. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.05.011 · Cited by 129
Zhao, Y., Feng, X., Chen, Y., Selfridge, J. E., Gorityala, S., Du, Z., Wang, J. M., Hao, Y., Cioffi, G., Conlon, R. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0600 · Cited by 129
Disruption of Amino Acid Homeostasis by Novel ASCT2 Inhibitors Involves Multiple Targets
Bröer, A., Fairweather, S., & Bröer, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00785 · Cited by 124
Cervantes-Madrid, D., Romero, Y., & Dueñas-González, A. (2015) · BioMed Research International · doi:10.1155/2015/690492 · Cited by 119
Role of Glutamine in Cancer: Therapeutic and Imaging Implications: FIGURE 1.
Rajagopalan, K. N., & DeBerardinis, R. J. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.084244 · Cited by 119
Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma
Ren, L., Ruiz‐Rodado, V., Dowdy, T., Huang, S., Issaq, S. H., Beck, J. A., Wang, H., Hoang, C. D., Lita, A., Larion, M., et al. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-0209-8 · Cited by 117
Cloning and functional characterization of a new subtype of the amino acid transport system N
Nakanishi, T., Kekuda, R., Fei, Y.-J., Hatanaka, T., Sugawara, M., Martindale, R. G., Leibach, F. H., Prasad, P. D., & Ganapathy, V. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.281.6.c1757 · Cited by 116
Soth, M., Le, K., Francesco, M. E. D., Hamilton, M. M., Liu, G., Burke, J. P., Carroll, C. L., Kovacs, J. J., Bardenhagen, J., Bristow, C. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01398 · Cited by 113
Lee, C.-H., Motzer, R., Emamekhoo, H., Matrana, M., Percent, I., Hsieh, J. J., Hussain, A., Vaishampayan, U., Liu, S., McCune, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0061 · Cited by 113
A one-gate elevator mechanism for the human neutral amino acid transporter ASCT2
Garaeva, A. A., Guskov, A., Slotboom, D. J., & Paulino, C. (2019) · Nature Communications · doi:10.1038/s41467-019-11363-x · Cited by 109
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy
Hartley, J. A. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1776255 · Cited by 109
Structural Basis for the Active Site Inhibition Mechanism of Human Kidney-Type Glutaminase (KGA)
Thangavelu, K., Chong, Q. Y., Low, B. C., & Sivaraman, J. (2014) · Scientific Reports · doi:10.1038/srep03827 · Cited by 107
Xiang, L., Xie, G., Liu, C., Zhou, J., Chen, J., Yu, S., Li, J., Pang, X., Shi, H., & Liang, H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.08.003 · Cited by 105
Magill, G. B., Myers, W. P. L., Reilly, H. C., Putnam, R. C., Magill, J. W., Sykes, M. P., Escher, G. C., Karnofsky, D. A., & Burchenal, J. H. (1957) · Cancer · doi:10.1002/1097-0142(195711/12)10:6<1138::aid-cncr2820100608>3.0.co;2-k · Cited by 104
Qie, S., Yoshida, A., Parnham, S., Oleinik, N., Beeson, G. C., Beeson, C. C., Ogretmen, B., Bass, A. J., Wong, K.-K., Rustgi, A. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09179-w · Cited by 104
Suppressive Effects of EGCG on Cervical Cancer
Wang, Y., Lu, J., Liang, Y., & Li, Q. (2018) · Molecules · doi:10.3390/molecules23092334 · Cited by 103
Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer
Lukey, M. J., Cluntun, A. A., Katt, W. P., Lin, M.-C. J., Druso, J. E., Ramachandran, S., Erickson, J. W., Le, H. H., Wang, Z.-E., Blank, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.076 · Cited by 103
New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+‐dependent anion leak
Grewer, C., & Grabsch, E. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.062521 · Cited by 102
Lowman, X. H., Hanse, E. A., Yang, Y., Ishak Gabra, M. B., Tran, T. Q., Li, H., & Kong, M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.037 · Cited by 102
Bröer, A., Gauthier-Coles, G., Rahimi, F., van Geldermalsen, M., Dorsch, D., Wegener, A., Holst, J., & Bröer, S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006378 · Cited by 101
Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation
Katt, W. P., Ramachandran, S., Erickson, J. W., & Cerione, R. A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0942 · Cited by 99
Glutaminase isoenzymes in the metabolic therapy of cancer
Matés, J. M., Campos-Sandoval, J. A., & Márquez, J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.007 · Cited by 98
Li, H., Yu, Y., Liu, Y., Luo, Z., Law, B. Y. K., Zheng, Y., Huang, X., & Li, W. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106306 · Cited by 98
Liu, J., Zhang, C., Lin, M., Zhu, W., Liang, Y., Hong, X., Zhao, Y., Young, K. H., Hu, W., & Feng, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.1862 · Cited by 97
Jiang, H., Zhang, N., Tang, T., Feng, F., Sun, H., & Qu, W. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104844 · Cited by 97
dos Reis, L. M., Adamóski, D., Souza, R. O. O., Ascenção, C. F. R., de Oliveira, K. R. S., Corrêa‐da‐Silva, F., Patroni, F. M. D. S., Dias, M. M., Consonni, S. R., Moraes‐Vieira, P. M., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008180 · Cited by 95
A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer
Kodama, M., Oshikawa, K., Shimizu, H., Yoshioka, S., Takahashi, M., Izumi, Y., Bamba, T., Tateishi, C., Tomonaga, T., Matsumoto, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15136-9 · Cited by 94
Glutamine, MTOR and autophagy: a multiconnection relationship
Bodineau, C., Tomé, M., Murdoch, P. D. S., & Durán, R. V. (2022) · Autophagy · doi:10.1080/15548627.2022.2062875 · Cited by 92
Ferreira, A. P. S., Cassago, A., Gonçalves, K. D. A., Dias, M. M., Adamoski, D., Ascenção, C. F. R., Honorato, R. V., de Oliveira, J. F., Ferreira, I. M., Fornezari, C., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.501346 · Cited by 89
Martín-Rufián, M., Nascimento-Gomes, R., Higuero, A., Crisma, A. R., Campos-Sandoval, J. A., Gómez-García, M. C., Cardona, C., Cheng, T., Lobo, C., Segura, J. A., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1105-2 · Cited by 88
Rho GTPases and their roles in cancer metabolism
Wilson, K. F., Erickson, J. W., Antonyak, M. A., & Cerione, R. A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.10.011 · Cited by 86
Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer
Huang, M., Xiong, D., Pan, J., Zhang, Q., Sei, S., Shoemaker, R. H., Lubet, R. A., Montuenga, L. M., Wang, Y., Slusher, B. S., et al. (2022) · Advanced Science · doi:10.1002/advs.202105885 · Cited by 86
Stalnecker, C. A., Ulrich, S. M., Li, Y., Ramachandran, S., McBrayer, M. K., DeBerardinis, R. J., Cerione, R. A., & Erickson, J. W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414056112 · Cited by 85
Pillai, R., LeBoeuf, S. E., Hao, Y., New, C., Blum, J. L. E., Rashidfarrokhi, A., Huang, S. M., Bahamon, C., Wu, W., Karadal-Ferrena, B., et al. (2024) · Science Advances · doi:10.1126/sciadv.adm9859 · Cited by 84
Yokoyama, Y., Estok, T. M., & Wild, R. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0282 · Cited by 81
SLC6A14 and SLC38A5 Drive the Glutaminolysis and Serine–Glycine–One-Carbon Pathways in Cancer
Sniegowski, T., Korać, K., Bhutia, Y. D., & Ganapathy, V. (2021) · Pharmaceuticals · doi:10.3390/ph14030216 · Cited by 80
Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment
Shen, Y., Chen, C., Huang, Y., Evans, E. E., Cheng, C., Chuang, Y.-J., Zhang, C., & Le, A. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.01.006 · Cited by 79
Hanaford, A. R., Alt, J., Rais, R., Wang, S. Z., Kaur, H., Thorek, D. L. J., Eberhart, C. G., Slusher, B. S., Martin, A. M., & Raabe, E. H. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.05.013 · Cited by 79
Mena, S., Benlloch, M., Ortega, A., Carretero, J., Obrador, E., Asensi, M., Petschen, I., Brown, B. D., & Estrela, J. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2642 · Cited by 78
Zhou, Q., Lin, W., Wang, C., Sun, F., Ju, S., Chen, Q., Wang, Y., Chen, Y., Li, H., Wang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30559-2 · Cited by 78
GPNA inhibits the sodium-independent transport system l for neutral amino acids
Chiu, M., Sabino, C., Taurino, G., Bianchi, M. G., Andreoli, R., Giuliani, N., & Bussolati, O. (2017) · Amino Acids · doi:10.1007/s00726-017-2436-z · Cited by 77 · cited 1×
“GPNA can inhibit ASCT2 and other glutamine transporters, such as sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, large neutral amino acid transporter 1 (LAT1), and LAT2, leading to decreased uptake of essential amino acids (Bröer et al., 2016; Chiu et al., 2017).”
BackgroundLi, X., Zhu, H., Sun, W., Yang, X., Nie, Q. H., & Fang, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02121-5 · Cited by 75
The role of L-type amino acid transporter 1 in human tumors
Zhao, Y. F., Wang, L., & Pan, J. (2015) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2015.01024 · Cited by 74
Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors
Thomas, A. G., Rojas, C., Tanega, C., Shen, M., Simeonov, A., Boxer, M. B., Auld, D. S., Ferraris, D. V., Tsukamoto, T., & Slusher, B. S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.110 · Cited by 73
Menchini, R. J., & Chaudhry, F. A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107789 · Cited by 72
Lopes, C., Pereira, C., & Medeiros, R. (2021) · Cancers · doi:10.3390/cancers13020203 · Cited by 72
Zhou, C., Guo, H., Willson, A. K., Yuan, L., Jones, H. M., Gehrig, P. A., Sheng, X., Zhang, L., Clark, L. H., & Bae-Jump, V. L. (2020) · PubMed · doi:10.17615/2xfe-5p09 · Cited by 71
Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy
Masamha, C. P., & LaFontaine, P. R. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26814 · Cited by 71
Meric‐Bernstam, F., Tannir, N. M., Iliopoulos, O., Lee, R. J., Telli, M. L., Fan, A. C., DeMichele, A. M., Haas, N. B., Patel, M. R., Harding, J. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2972 · Cited by 71
Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold
Zimmermann, S. C., Wolf, E. F., Luu, A., Thomas, A. G., Stathis, M. J., Poore, B., Nguyen, C. C., Le, A., Rojas, C. J., Slusher, B. S., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00060 · Cited by 70
The Role of EGCG in Breast Cancer Prevention and Therapy.
Romano, A., & Martel, F. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520999201211194445 · Cited by 70
Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia.
Lyons, S. D., Sant, M. E., & Christopherson, R. I. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38603-x · Cited by 69
Hoerner, C. R., Chen, V. J., & Fan, A. C. (2019) · Kidney Cancer · doi:10.3233/kca-180043 · Cited by 68
Lobetyolin induces apoptosis of colon cancer cells by inhibiting glutamine metabolism
He, W., Tao, W., Zhang, F., Jie, Q., He, Y., Zhu, W., Tan, J., Shen, W., Li, L., Yang, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15009 · Cited by 68
Colas, C., Grewer, C., Otte, N. J., Gameiro, A., Albers, T., Singh, K., Shere, H., Bonomi, M., Holst, J., & Schlessinger, A. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004477 · Cited by 67
Sikder, M. O. F., Yang, S., Ganapathy, V., & Bhutia, Y. D. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0164-7 · Cited by 64
Tenora, L., Alt, J., Dash, R. P., Gadiano, A. J., Novotná, K., Veeravalli, V., Lam, J., Kirkpatrick, Q. R., Lemberg, K. M., Majer, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b02009 · Cited by 64
Li, Q., Zhong, X., Yao, W., Yu, J., Wang, C., Li, Z., Lai, S., Qu, F., Fu, X., Huang, X., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101753 · Cited by 64
Self-citationvan Geldermalsen, M., Quek, L., Turner, N. A., Freidman, N., Pang, A., Guan, Y. F., Krycer, J. R., Ryan, R. M., Wang, Q., & Holst, J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4599-8 · Cited by 63
Role of Amino Acid Transporter SNAT1/SLC38A1 in Human Melanoma
Böhme, I., Lörentz, S., & Bosserhoff, A. (2022) · Cancers · doi:10.3390/cancers14092151 · Cited by 63
Ovejera, A. A., Houchens, D. P., Catane, R., Sheridan, M. A., & Muggia, F. M. (1979) · PubMed · Cited by 59
Harding, J. J., Telli, M. L., Munster, P. N., Le, M. H., Molineaux, C., Bennett, M. K., Mittra, E., Burris, H. A., Clark, A. S., Dunphy, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2512 · Cited by 58
The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling
Yamashita, A. S., Rosa, M. D. C., Stumpo, V., Rais, R., Slusher, B. S., & Riggins, G. J. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa149 · Cited by 57
Hidalgo, M. M., Rodriguez, G., Kuhn, J. G., Brown, T., Weiss, G. R., MacGovren, J. P., Hoff, D. D. V., & Rowinsky, E. K. (1998) · PubMed · Cited by 56
Tang, Y., Wang, S., Li, Y., Yuan, C., Zhang, J., Xu, Z., Hu, Y., Shi, H., & Wang, S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01424-7 · Cited by 56
Rational design of ASCT2 inhibitors using an integrated experimental-computational approach
Garibsingh, R.-A. A., Ndaru, E., Garaeva, A. A., Shi, Y., Zielewicz, L., Zakrepine, P., Bonomi, M., Slotboom, D. J., Paulino, C., Grewer, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104093118 · Cited by 55
Szeliga, M., Bogacińska-Karaś, M., Różycka, A., Hilgier, W., Marquez, J., & Albrecht, J. (2014) · Tumor Biology · doi:10.1007/s13277-013-1247-4 · Cited by 54
Wang, D., Meng, G., Zheng, M., Zhang, Y., Chen, A., Wu, J., & Wei, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166423 · Cited by 54
Inhibition of SLC1A 5 sensitizes colorectal cancer to cetuximab
Ma, H., Wu, Z., Peng, J., Li, Y., Huang, H., Liao, Y., Zhou, M., Sun, L., Huang, N., Shi, M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31274 · Cited by 52
Xie, J., Li, P., Gao, H., Qian, J., Yuan, L., & Wang, J. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-70 · Cited by 51
Self-citationLe, C. T., Leenders, W. P. J., Molenaar, R. J., & Noorden, C. J. F. V. (2018) · Nutrition and Cancer · doi:10.1080/01635581.2018.1446090 · Cited by 50
Luo, Z., Xu, J., Sun, J., Huang, H., Zhang, Z., Ma, W., Wan, Z., Liu, Y., Pardeshi, A., & Li, S. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.01.019 · Cited by 50
Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway
Lu, T., Li, M., Zhao, M., Huang, Y., Bi, G., Liang, J., Chen, Z., Zheng, Y., Xi, J., Lin, Z., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03116-x · Cited by 50
Poonaki, E., Nickel, A., Ardestani, M. S., Rademacher, L., Kaul, M., Apartsin, E. K., Meuth, S. G., Gorji, A., Janiak, C., & Kahlert, U. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105479 · Cited by 50
LAT1, a novel pharmacological target for the treatment of glioblastoma
Cappoli, N., Jenkinson, M. D., Russo, C. D., & Dickens, D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115103 · Cited by 50
Discovery and development of small molecule modulators targeting glutamine metabolism
Li, L., Meng, Y., Li, Z., Dai, W., Xu, X., Bi, X., & Bian, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.066 · Cited by 49
Self-citationCombined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer
Cohen, A. S., Geng, L., Zhao, P., Fu, A., Schulte, M. L., Graves-Deal, R., Washington, M. K., Berlin, J., Coffey, R. J., & Manning, H. C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100828 · Cited by 49
Wang, W., Pan, H., Ren, F., Chen, H., & Ren, P. (2022) · Bioscience Reports · doi:10.1042/bsr20212171 · Cited by 49
Cysteine is not a substrate but a specific modulator of human ASCT2 (SLC1A5) transporter
Scalise, M., Pochini, L., Pingitore, P., Hedfalk, K., & Indiveri, C. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.10.011 · Cited by 48
Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer
Wang, L., Liu, Y., Zhao, T., Li, Z., He, J., Zhang, B.-J., Du, H., Jiang, J., Yuan, S., & Sun, L. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.12.011 · Cited by 48
Self-citationXie, C., Jin, J., Bao, X., Zhan, W.-H., Han, T.-Y., Gan, M., Zhang, C., & Wang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.6311 · Cited by 47 · cited 1×
“Compound 968 can not only effectively inhibit the proliferation of cancer cells (Katt et al., 2012; Yuan et al., 2016), but also enhance the sensitivity of cancer cells to chemotherapy drugs or metabolic signaling inhibitors (Xie et al., 2016; Wang et al., 2021; Guo et al., 2023).”
BackgroundAllele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2
Redis, R. S., Vela, L. E., Lu, W., de Oliveira, J. F., Ivan, C., Rodriguez‐Aguayo, C., Adamóski, D., Pasculli, B., Taguchi, A., Chen, Y., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.006 · Cited by 47
Structural basis for exploring the allosteric inhibition of human kidney type glutaminase
Ramachandran, S., Pan, C. Q., Zimmermann, S. C., Duvall, B., Tsukamoto, T., Low, B. C., & Sivaraman, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10791 · Cited by 47
Sasakawa, A., Hosomi, K., Sumitomo, Y., Takizawa, T., Tomura-Suruki, S., Imaizumi, M., Kasai, N., Poh, T. W., Yamano, K., Yong, W. P., et al. (2018) · Europe PMC (PubMed Central) · Cited by 47
Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication
Zhao, L., Rao, X., Zheng, R., Huang, C., Kong, R., Yu, X., Cheng, H. B., & Li, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.027 · Cited by 47
Wang, J., Siu, M. K.-Y., Jiang, Y., Leung, T. H.-Y., Chan, D. W., Wang, H., Ngan, H., & Chan, K. K. L. (2021) · Biomolecules · doi:10.3390/biom11121749 · Cited by 46
Wang, E. S., Frankfurt, O., Orford, K. W., Bennett, M. K., Flinn, I. W., Maris, M. B., & Konopleva, M. Y. (2015) · Blood · doi:10.1182/blood.v126.23.2566.2566 · Cited by 45
Research works printed but not linked: 1
- Mickle, 2022, VGLL4 and glutamine deprivation suppress YAP1/TEAD signaling to attenuate the SCC cancer phenotype
Cited by
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Role of monocarboxylate transporters in cancer immunology and their therapeutic potential
Faghihkhorasani, F., Moosavi, M., Abdulwahid, A. R. R., Kavei, M., Karimi, S., Karimi, M. S., Vezvaei, P., Varkiani, M. M., Aref, A. R., & Ebrahimi, N. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70110 · Cited by 27
Li, Y., Lu, Y., Lü, W., Zhong, N., Li, N., Xu, Z., Zhang, J., Sun, H., Wu, F., Teng, Z., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113739 · Cited by 21
Lin, Z., Chang, C., Zhao, S., Fang, L., & Wang, P. (2025) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2025.0115 · Cited by 27
Deciphering the landscape of allosteric glutaminase 1 inhibitors as anticancer agents
Vagaggini, C., D’Ursi, P., Poggialini, F., Fossa, P., Francesconi, V., Trombetti, G., Orro, A., Dreassi, E., Schenone, S., Tonelli, M., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108523 · Cited by 17
Metadata
- Authors
- Fan, Y., Xue, H., Li, Z., Huo, M., Gao, H., & Guan, X.
- Affiliations
- Beihua University (CN)
- Taizhou University (CN)
- Corresponding author
- Gao, Hongxia
- Guan, Xingang
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2024-03-06
- Volume
- 15
- Pages
- 1345522-1345522
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10952006
- OpenAlex
- W4392517467
- Cited by
- 40
- References
- 263
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 3
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China
- Beihua University
- Science and Technology Plan Project of Taizhou (22gya03)
- Natural Science Foundation of Zhejiang Province (LY23C100001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- glutamine metabolism, cancer metabolism, glutaminase inhibitors, tumor metabolic reprogramming, TCA cycle, lipogenesis, cancer therapy, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.